Amgen (AMGN) ended the recent trading session at $322.67, demonstrating a +1.12% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.13%.

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...